Indication: Rocuronium bromide is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Insight:
- Dosing: Individualize the dose for each patient.
- Dosage forms: 5 mL multiple dose vials containing 50 mg rocuronium bromide injection (10 mg/mL), 10 mL multiple dose vials containing 100 mg rocuronium bromide injection (10 mg/mL).
- Adverse events: Most common adverse reactions (2%) are transient hypotension and hypertension.
- Mechanism of action: Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor endplate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.
- Manufacturer: Teva Pharmaceuticals
Sources: